Germany’s CureVac AG won approval to start human trials of its COVID-19 vaccines. Regulators have given the company the approval to test the shot in first-phase trials on 168 health people. This is second such treatment to go into clinical testing in Germany. The vaccine is based on a messenger RNA, in which the vaccine teaches the body’s cells to identify and attack the virus.

Leave a comment